Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.62 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PEPD | P12955 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13952183 | 1.00 | EPHX1 (0.62) | EPHX1CA1CA2CA4MEN1 | |
| SCHEMBL791505 | 1.00 | EPHX1 (0.62) | EPHX1CA1CA2CA4MEN1 | |
| SCHEMBL10556768 | 1.00 | EPHX1 (0.62) | EPHX1CA1CA2CA4MEN1 | |
| SCHEMBL301766 | 1.00 | EPHX1 (0.62) | EPHX1CA1CA2CA4MEN1 | |
| SCHEMBL3382944 | 1.00 | EPHX1 (0.62) | EPHX1CA1CA2CA4MEN1 | |
| SCHEMBL265657 | 1.00 | EPHX1 (0.62) | EPHX1CA1CA2CA4MEN1 | |
| SCHEMBL9885352 | 1.00 | EPHX1 (0.62) | EPHX1CA1CA2CA4MEN1 | |
| SCHEMBL11930055 | 1.00 | EPHX1 (0.62) | EPHX1CA1CA2CA4MEN1 | |
| SCHEMBL6917395 | 0.97 | EPHX1 (0.60) | EPHX1CA1CA2CA4MEN1 | |
| SCHEMBL12529955 | 0.97 | EPHX1 (0.60) | EPHX1CA1CA2CA4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1882684-B1 | PYRROLIDINE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2014-12-10 | — | — | EP | disclosed |
| US-8629126-B2 | Quinolone derivative or pharmaceutically acceptable salt thereof | ASTELLAS PHARMA INC. (JP) | 2014-01-14 | — | — | US | disclosed |
| US-20120136025-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2012-05-31 | — | — | US | disclosed |
| US-8133882-B2 | Quinolone derivative or pharmaceutically acceptable salt thereof | ASTELLAS PHARMA INC (JP) | 2012-03-13 | — | — | US | disclosed |
| US-8133882-B2 | Quinolone derivative or pharmaceutically acceptable salt thereof | ASTELLAS PHARMA INC (JP) | 2012-03-13 | — | — | US | disclosed |
| EP-1995240-B1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2012-02-22 | — | — | EP | disclosed |
| US-7585886-B2 | Pyrrolidine derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2009-09-08 | — | — | US | disclosed |
| US-7585886-B2 | Pyrrolidine derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2009-09-08 | — | — | US | disclosed |
| US-20090197834-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-08-06 | — | — | US | disclosed |
| US-20090197834-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-08-06 | — | — | US | disclosed |
| EP-1632483-B1 | HETEROCYCLIC SUBSTITUTED CARBONYL DERIVATIVES AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | AVENTIS PHARMA INC (US) | 2008-10-29 | — | — | EP | disclosed |
| EP-1935887-A1 | Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | Aventis Pharmaceuticals, Inc. (US) | 2008-06-25 | — | — | EP | disclosed |
| EP-1882684-A1 | PYRROLIDINE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2008-01-30 | — | — | EP | disclosed |
| EP-0814073-B1 | Epimerization of 2- or 4-substituted cyclohexanecarboxylic acids | KATAYAMA SEISAKUSHO (JP) | 2001-09-12 | — | — | EP | disclosed |
| US-5831118-A | HEATING WITH POTASSIUM HYDROXIDE; ONE STEP | KATAYAMA SEIYAKUSYO CO., LTD. (JP) | 1998-11-03 | — | — | US | disclosed |
| EP-0814073-A1 | Epimerization of 2- or 4-substituted cyclohexanecarboxylic acids | KATAYAMA SEIYAKUSYO CO. Ltd. (JP) | 1997-12-29 | — | — | EP | disclosed |
| EP-0340971-B1 | Attractants for the Mediterranean fruit fly | US COMMERCE (US) | 1994-01-19 | — | — | EP | disclosed |
| EP-0340971-A3 | ATTRACTANTS FOR THE MEDITERRANEAN FRUIT FLY | THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce (US) | 1991-09-11 | — | — | EP | disclosed |
| EP-0340971-A2 | Attractants for the Mediterranean fruit fly | THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce (US) | 1989-11-08 | — | — | EP | disclosed |
| EP-0340971-A2 | Attractants for the Mediterranean fruit fly | THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce (US) | 1989-11-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120136025-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | P2RY10, P2RY12, P2RY11 | EPHX1 1767/4885CA1 4618/4885CA2 1044/4885 |
| US-20090197834-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | P2RY12, P2RY11, P2RY10 | EPHX1 1861/4885CA1 4324/4885CA2 595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.